Table 6.
NO Nanomedicines for Eye Disease Therapya
| Nanomedicine | NO donor | Release condition | Working mechanism of NO | Refs |
|---|---|---|---|---|
| β-galactosidase-loaded PMA capsules | β-gal-NONOate | β-galactosidase | NO-mediated IOP-lowering therapeutics | 143 |
| HOS-JRLO | JS-K/L-Arginine | ascorbic acid/iNOS | HOS-JRLO generates more NO to induce a larger IOP reduction | 144 |
| PEG-PAspTETA-SNO | R-SNO | GSH | Alleviating high intraocular pressure in mice with glaucoma | 256 |
| pH@MSN-CaP-NO | diazeniumdiolate | pH 5.0 | NO promotes cornea wound healing | 147 |
| BP1 Vesicles | NBN, pNBN, BN | UV 365 nm irradiation | NO stimulates cornea wound healing | 149 |
| BPEI-NO NPs | NONOate | Physiological conditions | NO improves ocular wound recovery | 257 |
a
HOS-JRLO, hollow mesoporous organosilica-JS-K-L-Arginine; PEG-PAspTETA-SNO, PEG-poly(2-acetamido-N-triethylenetetramine-3-nitrosothiol-3-methylbutanamide) aspartamide-S-nitrosothiols; BP Vesicles, PEO45-b-PoNBNn Vesicles; BPEI-NO NPs, silica nanoparticles-branched polyethylene imine-N-diazeniumdiolates.